Titre : Séquences d'acides nucléiques régulatrices

Séquences d'acides nucléiques régulatrices : Questions médicales fréquentes

Termes MeSH sélectionnés :

Angiotensin-Converting Enzyme 2
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Séquences d'acides nucléiques régulatrices : Questions médicales les plus fréquentes", "headline": "Séquences d'acides nucléiques régulatrices : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Séquences d'acides nucléiques régulatrices : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-21", "dateModified": "2025-04-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Séquences d'acides nucléiques régulatrices" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Structures génétiques", "url": "https://questionsmedicales.fr/mesh/D040342", "about": { "@type": "MedicalCondition", "name": "Structures génétiques", "code": { "@type": "MedicalCode", "code": "D040342", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Réseaux de régulation génique", "alternateName": "Gene Regulatory Networks", "url": "https://questionsmedicales.fr/mesh/D053263", "about": { "@type": "MedicalCondition", "name": "Réseaux de régulation génique", "code": { "@type": "MedicalCode", "code": "D053263", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.080.689.360" } } }, { "@type": "MedicalWebPage", "name": "Séquences régulatrices de l'acide ribonucléique", "alternateName": "Regulatory Sequences, Ribonucleic Acid", "url": "https://questionsmedicales.fr/mesh/D038621", "about": { "@type": "MedicalCondition", "name": "Séquences régulatrices de l'acide ribonucléique", "code": { "@type": "MedicalCode", "code": "D038621", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.080.689.687" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Sites internes d'entrée des ribosomes", "alternateName": "Internal Ribosome Entry Sites", "url": "https://questionsmedicales.fr/mesh/D000067556", "about": { "@type": "MedicalCondition", "name": "Sites internes d'entrée des ribosomes", "code": { "@type": "MedicalCode", "code": "D000067556", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.080.689.687.093" } } }, { "@type": "MedicalWebPage", "name": "Riborégulateur", "alternateName": "Riboswitch", "url": "https://questionsmedicales.fr/mesh/D058928", "about": { "@type": "MedicalCondition", "name": "Riborégulateur", "code": { "@type": "MedicalCode", "code": "D058928", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.080.689.687.124" } } } ] }, { "@type": "MedicalWebPage", "name": "Séquence d'encapsidation virale", "alternateName": "Viral Packaging Sequence", "url": "https://questionsmedicales.fr/mesh/D000086502", "about": { "@type": "MedicalCondition", "name": "Séquence d'encapsidation virale", "code": { "@type": "MedicalCode", "code": "D000086502", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.080.689.905" } } } ], "about": { "@type": "MedicalCondition", "name": "Séquences d'acides nucléiques régulatrices", "alternateName": "Regulatory Sequences, Nucleic Acid", "code": { "@type": "MedicalCode", "code": "D012045", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Chad A Mirkin", "url": "https://questionsmedicales.fr/author/Chad%20A%20Mirkin", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Xiaolei Zuo", "url": "https://questionsmedicales.fr/author/Xiaolei%20Zuo", "affiliation": { "@type": "Organization", "name": "Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127 China." } }, { "@type": "Person", "name": "Qian Li", "url": "https://questionsmedicales.fr/author/Qian%20Li", "affiliation": { "@type": "Organization", "name": "School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, 200240 China." } }, { "@type": "Person", "name": "Chunhai Fan", "url": "https://questionsmedicales.fr/author/Chunhai%20Fan", "affiliation": { "@type": "Organization", "name": "Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127 China." } }, { "@type": "Person", "name": "Hanadi F Sleiman", "url": "https://questionsmedicales.fr/author/Hanadi%20F%20Sleiman", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, McGill University, 801 Sherbrooke St W, Montréal, QC H3A 08B, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Dynamics of the interaction between the receptor-binding domain of SARS-CoV-2 Omicron (B.1.1.529) variant and human angiotensin-converting enzyme 2.", "datePublished": "2022-07-05", "url": "https://questionsmedicales.fr/article/35811809", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7717/peerj.13680" } }, { "@type": "ScholarlyArticle", "name": "Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension.", "datePublished": "2023-04-18", "url": "https://questionsmedicales.fr/article/37071566", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acsnano.2c12190" } }, { "@type": "ScholarlyArticle", "name": "Angiotensin-Converting Enzyme 2 Potentiates SARS-CoV-2 Infection by Antagonizing Type I Interferon Induction and Its Down-Stream Signaling Pathway.", "datePublished": "2022-07-12", "url": "https://questionsmedicales.fr/article/35862802", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1128/msphere.00211-22" } }, { "@type": "ScholarlyArticle", "name": "Diffusion-Induced Ingress of Angiotensin-Converting Enzyme 2 into the Charge Conducting Path of a Pentacene Channel for Efficient Detection of SARS-CoV-2 in Saliva Samples.", "datePublished": "2022-09-21", "url": "https://questionsmedicales.fr/article/36129125", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acssensors.2c01287" } }, { "@type": "ScholarlyArticle", "name": "Decoding molecular factors shaping human angiotensin converting enzyme 2 receptor usage by spike glycoprotein in lineage B beta-coronaviruses.", "datePublished": "2022-08-04", "url": "https://questionsmedicales.fr/article/35932890", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.bbadis.2022.166514" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Structures génétiques", "item": "https://questionsmedicales.fr/mesh/D040342" }, { "@type": "ListItem", "position": 4, "name": "Séquences d'acides nucléiques régulatrices", "item": "https://questionsmedicales.fr/mesh/D012045" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Séquences d'acides nucléiques régulatrices - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Séquences d'acides nucléiques régulatrices", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Séquences d'acides nucléiques régulatrices", "description": "Comment identifier une séquence régulatrice ?\nQuels tests sont utilisés pour analyser les séquences régulatrices ?\nPeut-on détecter des mutations dans ces séquences ?\nQuels marqueurs sont associés aux séquences régulatrices ?\nComment évaluer l'activité d'une séquence régulatrice ?", "url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Angiotensin-Converting+Enzyme+2&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Séquences d'acides nucléiques régulatrices", "description": "Quels symptômes sont liés à des anomalies régulatrices ?\nLes séquences régulatrices affectent-elles le développement ?\nPeut-on observer des symptômes neurologiques ?\nLes troubles hormonaux sont-ils liés à ces séquences ?\nY a-t-il des symptômes immunologiques associés ?", "url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Angiotensin-Converting+Enzyme+2&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Séquences d'acides nucléiques régulatrices", "description": "Comment prévenir les maladies liées aux séquences régulatrices ?\nLes conseils génétiques sont-ils utiles ?\nPeut-on éviter les mutations par des choix de vie ?\nLes vaccinations jouent-elles un rôle ?\nY a-t-il des programmes de sensibilisation ?", "url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Angiotensin-Converting+Enzyme+2&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Séquences d'acides nucléiques régulatrices", "description": "Quels traitements ciblent les séquences régulatrices ?\nPeut-on corriger des mutations régulatrices ?\nLes traitements sont-ils personnalisés ?\nQuels sont les défis des traitements ?\nY a-t-il des essais cliniques en cours ?", "url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Angiotensin-Converting+Enzyme+2&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Séquences d'acides nucléiques régulatrices", "description": "Quelles complications peuvent survenir ?\nLes complications sont-elles héréditaires ?\nComment les complications sont-elles gérées ?\nY a-t-il des risques de récidive ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Angiotensin-Converting+Enzyme+2&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Séquences d'acides nucléiques régulatrices", "description": "Quels sont les facteurs de risque génétiques ?\nL'environnement influence-t-il ces séquences ?\nLe mode de vie joue-t-il un rôle ?\nLes infections sont-elles un facteur de risque ?\nY a-t-il des facteurs de risque liés à l'âge ?", "url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Angiotensin-Converting+Enzyme+2&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier une séquence régulatrice ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par des techniques comme la PCR et le séquençage." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour analyser les séquences régulatrices ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests comme l'empreinte génétique et l'analyse de l'expression génique sont utilisés." } }, { "@type": "Question", "name": "Peut-on détecter des mutations dans ces séquences ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations peuvent être détectées par séquençage ciblé ou NGS." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux séquences régulatrices ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs épigénétiques comme la méthylation de l'ADN sont souvent associés." } }, { "@type": "Question", "name": "Comment évaluer l'activité d'une séquence régulatrice ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'activité peut être évaluée par des essais de reporter génique." } }, { "@type": "Question", "name": "Quels symptômes sont liés à des anomalies régulatrices ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies peuvent entraîner des maladies génétiques, des cancers ou des troubles métaboliques." } }, { "@type": "Question", "name": "Les séquences régulatrices affectent-elles le développement ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles jouent un rôle crucial dans le développement embryonnaire et cellulaire." } }, { "@type": "Question", "name": "Peut-on observer des symptômes neurologiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations régulatrices peuvent être liées à des troubles neurologiques." } }, { "@type": "Question", "name": "Les troubles hormonaux sont-ils liés à ces séquences ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des séquences régulatrices peuvent influencer la régulation hormonale." } }, { "@type": "Question", "name": "Y a-t-il des symptômes immunologiques associés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies peuvent entraîner des dysfonctionnements du système immunitaire." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux séquences régulatrices ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par le dépistage génétique et la sensibilisation aux facteurs de risque." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils utiles ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils aident à évaluer le risque et à prendre des décisions éclairées." } }, { "@type": "Question", "name": "Peut-on éviter les mutations par des choix de vie ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Certains choix de vie, comme l'alimentation et l'exercice, peuvent réduire les risques." } }, { "@type": "Question", "name": "Les vaccinations jouent-elles un rôle ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent prévenir des infections qui influencent l'expression génique." } }, { "@type": "Question", "name": "Y a-t-il des programmes de sensibilisation ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des programmes éducatifs sensibilisent aux maladies génétiques et à leur prévention." } }, { "@type": "Question", "name": "Quels traitements ciblent les séquences régulatrices ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments ciblant des voies spécifiques sont en développement." } }, { "@type": "Question", "name": "Peut-on corriger des mutations régulatrices ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques comme CRISPR permettent de corriger certaines mutations." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la médecine personnalisée adapte les traitements selon le profil génétique." } }, { "@type": "Question", "name": "Quels sont les défis des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les défis incluent la spécificité, l'efficacité et les effets secondaires potentiels." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques en cours ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux essais cliniques explorent des thérapies ciblant ces séquences." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des cancers, des troubles métaboliques et des maladies auto-immunes." } }, { "@type": "Question", "name": "Les complications sont-elles héréditaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être héréditaires, liées à des mutations dans les séquences régulatrices." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi médical régulier et des traitements adaptés." } }, { "@type": "Question", "name": "Y a-t-il des risques de récidive ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles peuvent avoir un risque de récidive, nécessitant une surveillance." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque génétiques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents familiaux de maladies génétiques augmentent le risque." } }, { "@type": "Question", "name": "L'environnement influence-t-il ces séquences ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs environnementaux comme les toxines peuvent affecter l'expression génique." } }, { "@type": "Question", "name": "Le mode de vie joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes comme le tabagisme et l'alimentation peuvent influencer le risque." } }, { "@type": "Question", "name": "Les infections sont-elles un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections peuvent déclencher des modifications dans les séquences régulatrices." } }, { "@type": "Question", "name": "Y a-t-il des facteurs de risque liés à l'âge ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de maladies génétiques augmente avec l'âge." } } ] } ] }

Sources (10000 au total)

Dynamics of the interaction between the receptor-binding domain of SARS-CoV-2 Omicron (B.1.1.529) variant and human angiotensin-converting enzyme 2.

The COVID-19 pandemic is still a global public health issue. Omicron, a SARS-CoV-2 B.1.1.529 variant, has raised concerns about transmission and vaccine effectiveness. Omicron currently has the greate... To gain a better understanding of the significance of these variations and the dynamics of the interaction between the Omicron spike (S) protein and its human host factor angiotensin-converting enzyme... Though mutations K417N and G496S in the S protein RBD disrupt interactions found in the original SARS-CoV-2 complex, mutations Q493R and N501Y introduce interactions not found in the original complex....

Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension.

Hypoxic pulmonary hypertension (HPH) is characterized by pulmonary vascular sustained constriction and progressive remodeling, which are initiated by hypoxia then with hypoxia-induced additive factors...

Diffusion-Induced Ingress of Angiotensin-Converting Enzyme 2 into the Charge Conducting Path of a Pentacene Channel for Efficient Detection of SARS-CoV-2 in Saliva Samples.

Rapid and accurate identification of a pathogen is crucial for disease control and prevention of the epidemic of emerging infectious like SARS-CoV-2. However, no foolproof gold standard assay exists t...

Decoding molecular factors shaping human angiotensin converting enzyme 2 receptor usage by spike glycoprotein in lineage B beta-coronaviruses.

Acquiring the human ACE2 receptor usage trait enables the coronaviruses to spill over to humans. However, the origin of the ACE2 usage trait in coronaviruses is poorly understood. Using a multi-discip...

Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3).

ACE cleaves angiotensin I (Ang I) to angiotensin II (Ang II) inducing vasoconstriction via Ang II type 1 (AT1) receptor, while ACE2 cleaves Ang II to Ang (1-7) causing vasodilatation by acting on the ... Among 777 participants with diabetes enrolled in the Urinary biomarker for Continuous And Rapid progression of diabetic nEphropathy study, the 296 patients followed up for 9 years were investigated. P... The cumulative incidence of the renal composite outcome was significantly higher in group 1 with lowest tertile of plasma ACE2 (p=0.040). Group 2 with middle and highest tertile was associated with be... Higher baseline plasma ACE2 levels in DKD were protective for development and progression of albuminuria and associated with fewer renal end points, suggesting plasma ACE2 may be used as a prognosis m... UMIN000011525....

Comparison of truncated human angiotensin-converting enzyme 2 (hACE2) expression in pET28a(+) versus pET-SUMO vector and two Escherichia coli strains.

Truncated human angiotensin-converting enzyme 2 (hACE2) expression rises a great scientific interest, considering its possible therapeutic and diagnostic applications. A promising research direction i... The encoding DNA for the hACE2 fragments (7-507 aa, 16-128 aa, and 30-357 aa) was obtained by PCR amplification using as template pcDNA3.1-hACE2 plasmid and further cloned into pET28a(+) and pET-SUMO ... For all three truncated hACE2 mini proteins, pET28a(+) does not lead to protein expression, regardless of the bacterial strain. The situation changes with the use of the pET-SUMO expression system whe... In the present study, we showed that different versions of recombinant hACE2 are successfully expressed in E. coli BL21(DE3) by using pET-SUMO expression system....

The Cholesterol-Binding Sequence in Monomeric C-Reactive Protein Binds to the SARS-CoV-2 Spike Receptor-Binding Domain and Blocks Interaction With Angiotensin-Converting Enzyme 2.

The receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the human angiotensin-converting enzyme 2 (ACE2) receptor, which is a pr...